Lexaria Bioscience (LEXX) investor relations material

Company overview and technology

• Clinical-stage company focused on oral drug delivery using proprietary DehydraTECH platform for peptides and small molecules.

• DehydraTECH enables rapid onset, increased oral bioavailability, and enhanced CNS biodistribution.

• Platform offers exceptional gastrointestinal safety, shelf stability, low manufacturing costs, and flexible dosage forms.

• Robust patent portfolio with 65 granted patents and many pending globally.

DehydraTECH for GLP-1 drugs (diabetes/weight loss)

• Human and animal studies conducted with semaglutide, tirzepatide, and liraglutide, showing improved safety and pharmacokinetics.

• DehydraTECH formulations consistently reduced total and GI adverse events by up to 100% compared to controls.

• Oral DehydraTECH-tirzepatide achieved blood level parity with injectable Zepbound® and showed higher brain biodistribution.

• Phase 1b study met primary endpoints for safety and tolerability, with comparable efficacy to Rybelsus®.

• Potential for world's first oral liraglutide product via 505(b)(2) pathway.

DehydraTECH-CBD for hypertension

• Addressing a large market with 1.3 billion hypertensive adults globally and $24B+ market size.

• Five clinical studies showed significant blood pressure reductions, superior safety, and no serious adverse events.

• DehydraTECH-CBD achieved nearly 3x higher blood absorption than Epidiolex®.

• FDA IND clearance for Phase 1b trial in stage 1/2 hypertension; study initiation pending funding.

• Demonstrated potential to treat resistant hypertension with a novel mechanism of action.